Functional Evaluation of Edible Mushrooms and Their Active Materials

A special issue of Nutrients (ISSN 2072-6643). This special issue belongs to the section "Phytochemicals and Human Health".

Deadline for manuscript submissions: 25 November 2024 | Viewed by 3818

Special Issue Editors


E-Mail Website
Guest Editor
1. Engineering Research Center of Chinese Ministry of Education for Edible and Medicinal Fungi, Jilin Agricultural University, Changchun 130118, China
2. School of Life Sciences, Jilin University, Changchun 130012, China
Interests: fungi; natural compounds; pharmacological efficacy
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Engineering Research Center of Chinese Ministry of Education for Edible and Medicinal Fungi, Jilin Agricultural University, Changchun 130118, China
Interests: fungi; natural compounds; pharmacological efficacy; brain diseases

E-Mail Website
Guest Editor
Engineering Research Center of Chinese Ministry of Education for Edible and Medicinal Fungi, Jilin Agricultural University, Changchun 130118, China
Interests: active polysaccharide; fungi

Special Issue Information

Dear Colleagues,

In recent years, edible mushrooms have been increasingly studied due to the various effects they can have on human health. Mushrooms, such as Ganoderma sichuanense and Lentinula edodes, have been applied in clinical settings. However, many edible mushrooms are not well-known, and their properties have not yet been thoroughly studied. Additionally, the mechanisms involved in their effects, including their target cells and molecules, remain unclear.

The goal of this Special Issue is to explore the function of mushrooms and their active compounds and to clarify their mechanism of action and targets. Submitted manuscripts should adhere to the following requirements and scope:

  1. The studied active materials must include an edible mushroom (including wild or cultivated fungi) or its active ingredient(s), which should have strong application prospects;
  2. The pharmacological effects of the mushroom(s) or their active material(s) should be described, which includes, but is not limited to, immune-regulatory, anti-inflammatory, anti-neurodegeneration, antioxidative and antitumor properties. Data obtained from in vitro experiments must be confirmed using animal models or, preferably, through clinical trials;
  3. The study must clarify the mechanisms of action of the studied compounds, with a clear delineation of the targets, such as cells and cytokines associated with the identified efficacies.

Prof. Dr. Di Wang
Dr. Chunyue Wang
Dr. Yang Liu
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Nutrients is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • edible mushroom
  • active materials
  • efficacies
  • animal models
  • clinical trials
  • target cells/molecules

Published Papers (3 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

15 pages, 6560 KiB  
Article
Intestinal Microbiota and Metabolomics Reveal the Role of Auricularia delicate in Regulating Colitis-Associated Colorectal Cancer
by Lanzhou Li, Honghan Liu, Jinqi Yu, Zhen Sun, Ming Jiang, Han Yu and Chunyue Wang
Nutrients 2023, 15(23), 5011; https://doi.org/10.3390/nu15235011 - 04 Dec 2023
Cited by 1 | Viewed by 1169
Abstract
Background: The edible fungus Auricularia delicate (ADe) is commonly employed in traditional medicine for intestinal disorders; however, its inhibitory effect on colitis-associated colorectal cancer (CAC) and the underlying mechanisms remain unexplored. (2) Methods: The inhibitory effect of ADe on CAC was investigated using [...] Read more.
Background: The edible fungus Auricularia delicate (ADe) is commonly employed in traditional medicine for intestinal disorders; however, its inhibitory effect on colitis-associated colorectal cancer (CAC) and the underlying mechanisms remain unexplored. (2) Methods: The inhibitory effect of ADe on CAC was investigated using a mouse model induced by azoxymethane/dextran sulfate sodium. Results: ADe effectively suppressed the growth and number of intestinal tumors in mice. Intestinal microbiota analyses revealed that ADe treatment increased Akkermansia and Parabacteroides while it decreased Clostridium, Turicibacter, Oscillospira, and Desulfovibrio. ADe regulated the levels of 2′-deoxyridine, creatinine, 1-palmitoyl lysophosphatidylcholine, and choline in serum. Furthermore, the levels of these metabolites were associated with the abundance of Oscillospira and Paraacteroides. ADe up-regulated the free fatty acid receptor 2 and β-Arrestin 2, inhibited the nuclear factor kappa B (NF-κB) pathway, and significantly attenuated the levels of inflammatory cytokines, thereby mitigating the inflammatory in CAC mice. Conclusions: The protective effect of ADe in CAC mice is associated with the regulation of intestinal microbiota, which leads to the inhibition of NF-kB pathway and regulation of inflammation. Full article
(This article belongs to the Special Issue Functional Evaluation of Edible Mushrooms and Their Active Materials)
Show Figures

Graphical abstract

16 pages, 5683 KiB  
Article
Chroogomphus rutilus Regulates Bone Metabolism to Prevent Periodontal Bone Loss during Orthodontic Tooth Movement in Osteoporotic Rats
by Ying Zhou, Yanfeng Zhu, Xinghui Jin, Yongfeng Zhang, Jiyu Song, Zhina Wu, Yutong Li, Jingzheng Yi, Di Wang and Min Hu
Nutrients 2023, 15(23), 4906; https://doi.org/10.3390/nu15234906 - 24 Nov 2023
Viewed by 1007
Abstract
Osteoporosis (OP) leads to the acceleration of tooth movement and aggravation of periodontal bone loss during orthodontic treatment. Chroogomphus rutilus (CR) is abundant in nutrients and demonstrates remarkable antioxidant and anti-inflammatory properties. In the present study, the components of CR, including 35.00% total [...] Read more.
Osteoporosis (OP) leads to the acceleration of tooth movement and aggravation of periodontal bone loss during orthodontic treatment. Chroogomphus rutilus (CR) is abundant in nutrients and demonstrates remarkable antioxidant and anti-inflammatory properties. In the present study, the components of CR, including 35.00% total sugar, 0.69% reducing sugar, 14.40% crude protein, 7.30% total ash, 6.10% crude fat, 0.51% total flavonoids, 1.94% total triterpenoids, 0.32% total sterol, 1.30% total saponins, 1.69% total alkaloids, and 1.02% total phenol, were first systematically examined, followed by an investigation into its regulatory effects on bone metabolism in order to mitigate bone loss during orthodontic tooth movement in osteoporotic rats. The results of the imaging tests revealed that CR treatment reduced periodontal bone loss and normalized tooth movement in the OP. In conjunction with analyses of intestinal flora and metabolomics, CR enhances the prevalence of anti-inflammatory genera while reducing the production of inflammatory metabolites. Meanwhile, CR reduced the levels of periodontal inflammatory factors, including TNF-α, IL-1β, and IL-6, by activating Wnt/β-catenin signaling, and promoted periodontal bone formation. These findings imply that CR is a potent supplementary therapy for controlling periodontal bone remodeling in patients with OP undergoing orthodontic treatment. Full article
(This article belongs to the Special Issue Functional Evaluation of Edible Mushrooms and Their Active Materials)
Show Figures

Graphical abstract

17 pages, 5806 KiB  
Article
Pleurotus abieticola Polysaccharide Alleviates Hyperlipidemia Symptoms via Inhibition of Nuclear Factor-κB/Signal Transducer and Activator of Transcription 3-Mediated Inflammatory Responses
by Yongfeng Zhang, Yingjie Lin, Keyi Wu, Ming Jiang, Lanzhou Li and Yang Liu
Nutrients 2023, 15(23), 4904; https://doi.org/10.3390/nu15234904 - 23 Nov 2023
Viewed by 1005
Abstract
Hyperlipidemia (HLP) is a metabolic syndrome induced by obesity, which has been widely recognized as a significant threat to human health. Pleurotus abieticola, an edible lignin-degrading fungus, remains relatively understudied in terms of its bioactivity and medicinal properties. In this study, the [...] Read more.
Hyperlipidemia (HLP) is a metabolic syndrome induced by obesity, which has been widely recognized as a significant threat to human health. Pleurotus abieticola, an edible lignin-degrading fungus, remains relatively understudied in terms of its bioactivity and medicinal properties. In this study, the lipid-lowering effect of Pleurotus abieticola polysaccharide (PAPS1) was systematically explored in high-fat diet (HFD)-induced HLP mice. The findings demonstrated that the administration of PAPS1 significantly inhibited bodyweight gain, ameliorated blood glucose and lipid levels, reduced fat accumulation, and mitigated hepatic injury in HLP mice. In addition, PAPS1 demonstrated the capability to increase the levels of three distinct fecal metabolites while simultaneously reducing the levels of eight other fecal metabolites in HLP mice. According to biological detection, PAPS1 reduced the hepatic level of reactive oxygen species (ROS) and pro-inflammatory factors, such as tumor necrosis factor (TNF)-α and interleukin (IL)-1β, -6, -17A, -22, and -23, and increased the expression of anti-inflammatory factor IL-10. Combined with proteomics, Western blot and immunohistochemistry analysis showed that PAPS1 exerted suppressive effects on inflammation and oxidative damage by inhibiting the nuclear factor-κB (NF-κB)/signal transducer and activator of transcription 3 (STAT3) signaling pathway in HLP mice. These findings offer evidence supporting the effectiveness of PAPS1 as a therapeutic agent in reducing lipid levels through its targeting of chronic inflammation. Full article
(This article belongs to the Special Issue Functional Evaluation of Edible Mushrooms and Their Active Materials)
Show Figures

Figure 1

Back to TopTop